Up 7% in NY on the back of the West Palm Beach Court ruling. GSK similarly up. |
Interesting reading for you, PPE.
Verifiable fact. |
PPE. Where did you get that information? Or is it just your usual negative/scaemongering postings?
There hasn't been a single holdings RNS from any holder since this one on 4 August, which - strangely enough - happened to be regarding Pfizer's holding (which relates to their ORIGINAL holding):
Just make a note of how many shares Pfizer holds. It's hardly likely that they would have sold a tiny (relative) number of shares to ensure that they didn't have to make an announcement. What would be the point of that?
Please do try to post verifiable nonsense rather than absolute nonsense. |
Yeh right meanwhile Pfizer quietly sell off their holding. |
Trying to break out today above resistance. |
Anyone have any insight into when GSK and PFE will have liquidated their holdings here? |
PPE
Please stop posting this rubbish, or back it up with evidence! Trying to find some should keep you off this site for a while. |
There isn't any, it's total puff! |
Evidence please on that statement. |
Pfizer are already dumping shares since the overhang was lifted in November after Haleon rejects requests for indemnifications on Zantac. Pfizer needing to build a cash position to fund the over 2,000 tort legal cases pending in the Florida state court in mid 2023..A further 51 state courts litigations are also in the pipeline with global litigation in other non US jurisdictions pending. GSK likely to follow suite with exiting its Haleon holdings to fund Zantac litigation costs. |
These two stocks look like a good match to me :-) |
My blood pressure is synchronised with the crashing share price ! |
I worry for your blood pressure, you seem to follow every rise and fall of the share price like you were personally hitching a ride on it.. :O |
Crashing big time |
I was reading that JNJ are also planning to float off their consumer health division. |
Generally encouraging Q3 update today.
Happy to continue holding on these figures. |
Okay thanks |
FWIW...
27th oct Kepler hold tp 275p
14th oct Jefferies hold tp 280p
7th sept JP Morgan underweight tp 250p
16th aug RBC sect perform tp 300p
29th july Deutsche hold tp 300p
21st july Citigroup buy tp 360p
20th july BOA buy tp 385p
20th july Goldmans buy tp 350p
19th july UBS buy tp 380p
19th july Credit Suisse outperform tp 353p
19th july Barclays equal weight tp 347p |
I have no idea of the future share price of HLN but it's odd how the price has been rising lately in view of your repeated bearish comments.
If you really are interested in what brokers and press etc. think, you need to check out all of them and see what the balance of their opinion is, not just cherry pick those that agree with your predetermined view. That's called confirmation bias and is one of the large range of classic small investor mistakes.
I personally have no interest in such views but make up my own mind, which is that on balance HLN is more worth keeping than selling now. |
 'Wallet Investor’s Haleon long-term forecast indicated that the stock could be a non-viable investment. The algorithm-based forecasting service predicted that the share price could fall to £2.21 by the end of 2022 and decline throughout 2023 to trade at just £0.09 by the end of the year. The stock could effectively fall to zero by 2024, according to WalletInvestor’s forecast for the Haleon stock price in 5 years.
The Haleon stock 5-year forecast from Gov Capital similarly estimated that the American Depositary Receipts (ADRs) for Haleon listed in the US could drop to zero, but by November 2023.'
The most likely scenario is that due to the impact of generic drug labels, rising consumer inflation, and multi billion dollar Zantac litigation costs and settlements the share price will fall. The high burden of existing debt, rising interest rates, and flattening consumer sales reflected in the falling share price, note the price is down 16% since floatation with the expected off loading of both Pfizer and GSK's share holdings in November places more downward pressure on the share price on the foreseeable future. |
Haleon sales targets impress Barclays
Bank has a 347p target on the Sensodyne, Panadol and Centrum owner |
HALEON PLC
LON: HLN
OverviewNewsCompareFinancials
281.25 GBX -27.10 (-8.79%)past 1 month
7 Oct, 17:49 BST • Disclaimer |
PPE
Please check the facts.......Its a bargain at these price levels |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
